Sites
Tags
- Abemaciclib
- Acalabrutinib
- Acute interstitial pneumonitis
- Adjuvant therapy
- Adverse effect
- Afatinib
- Aflibercept
- Alectinib
- Alemtuzumab
- American Medical Association
- American Society of Health-System Pharmacists
- Amine
- Amitriptyline
- ANA-12
- Anaplastic lymphoma kinase
- Anemia
- Angiopoietin 1
- ANGPT2
- Antibody-drug conjugate
- Apoptosis
- Artemin
- Atezolizumab
- Avelumab
- Axitinib
- Baricitinib
- Basic fibroblast growth factor
- BBC News Online
- Bevacizumab
- Binimetinib
- Bioavailability
- Biological half-life
- Bosutinib
- Boxed warning
- Brain
- Brain-derived neurotrophic factor
- Brain metastasis
- Breakthrough therapy
- Breast
- Breast cancer
- Brigatinib
- Bruton's tyrosine kinase
- Burosumab
- Cabozantinib
- Cancer
- Cancer Drugs Fund
- Cancer immunotherapy
- Capecitabine
- CAS Registry Number
- CD117
- CD135
- CD20
- CD3
- CD30
- CD33
- CDK inhibitor
- Cell division
- Cerebrolysin
- Ceritinib
- Cetuximab
- ChEMBL
- Chemical formula
- Chemotherapy
- Clinical trial
- C-Met
- Covalent bond
- Crizotinib
- CTGF
- Cyclotraxin B
- CYP3A4
- CYP3A5
- Cytotoxicity
- DailyMed
- Daratumumab
- Dasatinib
- Dehydroepiandrosterone
- Dehydroepiandrosterone sulfate
- Developmental toxicity
- Dexamethasone
- Diosmetin
- Docetaxel
- DOI
- DrugBank
- Drug class
- Drug metabolism
- Drug nomenclature
- Durvalumab
- Duvelisib
- Ejection fraction
- Elevated transaminases
- Elotuzumab
- Enfortumab vedotin
- Ephrin
- Ephrin A1
- Ephrin B2
- Epidermal growth factor
- Epidermal growth factor receptor
- Epigen
- Epithelial cell adhesion molecule
- ErbB
- ERBB3
- ERBB4
- Erdafitinib
- Erlotinib
- Erythropoietin
- ESMO
- Ester
- European Medicines Agency
- Everolimus
- Evinacumab
- Exotoxin
- FDA
- Fedratinib
- FGF1
- FGF8
- Fibroblast growth factor
- Fibroblast growth factor 23
- Fibroblast growth factor receptor
- Fibroblast growth factor receptor 1
- Fibroblast growth factor receptor 2
- Fibroblast growth factor receptor 3
- Fibroblast growth factor receptor 4
- Filgotinib
- Food and Drug Administration
- Forecasting
- Functional
- Functional group
- Fusion protein
- Gefitinib
- Gemtuzumab ozogamicin
- Genentech
- Glial cell line-derived neurotrophic factor
- Glucose-6-phosphate isomerase
- Growth factor receptor
- Hedgehog signaling pathway
- Heparin-binding EGF-like growth factor
- Hepatic encephalopathy
- Hepatocyte growth factor
- Hepatotoxicity
- HER2/neu
- Hoffmann-La Roche
- Humanized antibody
- Ibritumomab tiuxetan
- Ibrutinib
- Idelalisib
- IGF-1 LR3
- IGFBP3
- IGFBP7
- Imatinib
- ImmunoGen
- Incyte
- Inotuzumab ozogamicin
- Insulin
- Insulin-like growth factor 1
- Insulin-like growth factor 1 receptor
- Insulin-like growth factor 2
- Insulin-like growth factor-binding protein
- Interleukin
- Interleukin 2
- Interstitial lung disease
- Intravenous therapy
- Ipilimumab
- Janus kinase
- KEGG
- Kraš
- Lapatinib
- Larotrectinib
- Leadership
- Lenvatinib
- Leukemia
- Leukemia inhibitory factor
- Liver
- Liver failure
- Long term
- Lonza Group
- Lorlatinib
- Low-affinity nerve growth factor receptor
- Lymphatic system
- Lymphoma
- Lysine
- Maleimide
- MAPK/ERK pathway
- Mecasermin rinfabate
- Medical error
- MedlinePlus
- Metastases
- Metástasis
- Metastatic breast cancer
- Microtubule
- Midkine
- Mitogen-activated protein kinase kinase
- Molar mass
- Monoclonal antibody
- Monoclonal antibody therapy
- Mouse
- MST1
- MTOR inhibitors
- Myeloid
- National Cancer Institute
- National Health Service
- Neratinib
- Nerve growth factor
- Neurotrophin-3
- New York Times
- Nice
- Nilotinib
- Nintedanib
- Nivolumab
- Non-receptor tyrosine kinase
- Obinutuzumab
- Ofatumumab
- Osimertinib
- P
- Paclitaxel
- Palbociclib
- Panitumumab
- Pazopanib
- PDGFB
- P element
- Pembrolizumab
- Peripheral neuropathy
- Pertuzumab
- Pharmaceutical drug
- Pharmaceutics
- Pharmacokinetics
- Philadelphia chromosome
- Phosphoinositide 3-kinase inhibitor
- PI3K/AKT/mTOR pathway
- Pituitary adenylate cyclase-activating peptide
- Placental growth factor
- Plasma protein binding
- Platelet
- Platelet-derived growth factor
- Platelet-derived growth factor receptor
- Pleiotrophin
- PMC
- Ponatinib
- Pre-clinical development
- Pregnancy category
- Prescription drug
- Priority review
- Progression-free survival
- Prohibitin
- PubChem
- Public domain
- PubMed
- Quality-adjusted life year
- Quizartinib
- R13
- R7
- Ramucirumab
- Ranibizumab
- Reagent
- Receptor modulator
- Receptor tyrosine kinase
- Regorafenib
- Regulation of therapeutic goods
- Reuters
- Ribociclib
- Rituximab
- Route of administration
- Ruxolitinib
- Sacituzumab govitecan
- Sega Wow
- Selegiline
- Semaxanib
- Signaling
- SIRT
- Small molecule
- Sonidegib
- Sorafenib
- SRC
- Standard for the Uniform Scheduling of Medicines and Poisons
- Standard of care
- Stem cell factor
- Stomach cancer
- Stomatitis
- Sunitinib
- Survival rate
- Targeted therapy
- Taxane
- Teprotumumab
- Testosterone
- TGF beta receptor
- Therapy
- The standard
- Thrombocytopenia
- Thrombopoietin
- Tositumomab
- Trametinib
- Trastuzumab
- Tremelimumab
- Trk receptor
- Tropomyosin receptor kinase A
- Tropomyosin receptor kinase B
- Tropomyosin receptor kinase C
- Tubulin
- Tucatinib
- Tyrosine-kinase inhibitor
- Vascular endothelial growth factor
- Vascular endothelial growth factor A
- Vascular endothelial growth factor B
- VEGF receptor
- Venetoclax
- Ventricle
- Vismodegib
- Wnt signaling pathway